Matinas BioPharma Holdings Inc Cash Flow Conversion Efficiency
Matinas BioPharma Holdings Inc cash flow conversion efficiency. Based on the latest financial reports, Matinas BioPharma Holdings Inc (MTNB) has a cash flow conversion efficiency ratio of -0.530x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.60 Million) by net assets ($3.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Matinas BioPharma Holdings Inc (2012–2025)
Cash flow conversion efficiency of Matinas BioPharma Holdings Inc from 2012 to 2025. This chart illustrates how Matinas BioPharma Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Matinas BioPharma Holdings Inc for real-time trading data and today's change.
Matinas BioPharma Holdings Inc Cash Flow Conversion Ratio Explained
Matinas BioPharma Holdings Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Matinas BioPharma Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Matinas BioPharma Holdings Inc ranked by their cash flow conversion efficiency. Also see MTNB market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Vision Marine Technologies Inc
NASDAQ:VMAR
|
0.338x |
|
Wirtek A/S
CO:WIRTEK
|
-0.058x |
|
Pryme BV
OL:PRYME
|
-1.603x |
|
Mears Group plc
LSE:MER
|
0.354x |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
-0.087x |
|
Odyssean Investment Trust PLC
LSE:OIT
|
0.000x |
|
Gooch & Housego Plc
LSE:GHH
|
0.046x |
|
Hydrotek Public Company Limited
BK:HYDRO
|
-0.054x |
Annual Cash Flow Conversion Efficiency for Matinas BioPharma Holdings Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Matinas BioPharma Holdings Inc from 2012 to 2025. Review Matinas BioPharma Holdings Inc (MTNB) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $4.83 Million | $-7.01 Million | -1.452x | +30.64% |
| 2024-12-31 | $7.59 Million | $-15.88 Million | -2.093x | -163.64% |
| 2023-12-31 | $19.25 Million | $-15.28 Million | -0.794x | -51.82% |
| 2022-12-31 | $36.64 Million | $-19.16 Million | -0.523x | -80.29% |
| 2021-12-31 | $52.49 Million | $-15.22 Million | -0.290x | -6.42% |
| 2020-12-31 | $63.73 Million | $-17.37 Million | -0.273x | +36.08% |
| 2019-12-31 | $33.05 Million | $-14.09 Million | -0.426x | +33.32% |
| 2018-12-31 | $16.14 Million | $-10.32 Million | -0.639x | +40.40% |
| 2017-12-31 | $10.68 Million | $-11.46 Million | -1.073x | -25.36% |
| 2016-12-31 | $7.15 Million | $-6.12 Million | -0.856x | +33.50% |
| 2015-12-31 | $6.07 Million | $-7.81 Million | -1.287x | +63.99% |
| 2014-12-31 | $2.23 Million | $-7.96 Million | -3.573x | -1152.77% |
| 2013-12-31 | $10.47 Million | $-2.99 Million | -0.285x | -69.33% |
| 2012-12-31 | $339.94K | $-57.26K | -0.168x | -- |
About Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an… Read more